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Abstract
Background: Sarcospan (SSPN) is a transmembrane protein that interacts with the sarcoglycans (SGs) to form a tight
subcomplex within the dystrophin-glycoprotein complex that spans the sarcolemma and interacts with laminin in the
extracellular matrix. Overexpression of SSPN ameliorates Duchenne muscular dystrophy in murine models.
Methods: Standard cloning approaches were used to identify nanospan, and nanospan-specific polyclonal antibodies
were generated and validated. Biochemical isolation of skeletal muscle membranes and two-photon laser scanning
microscopy were used to analyze nanospan localization in muscle from multiple murine models. Duchenne muscular
dystrophy biopsies were analyzed by immunoblot analysis of protein lysates as well as indirect immunofluorescence
analysis of muscle cryosections.
Results: Nanospan is an alternatively spliced isoform of sarcospan. While SSPN has four transmembrane domains and
is a core component of the sarcolemmal dystrophin-glycoprotein complex, nanospan is a type II transmembrane
protein that does not associate with the dystrophin-glycoprotein complex. We demonstrate that nanospan is enriched
in the sarcoplasmic reticulum (SR) fractions and is not present in the T-tubules. SR fractions contain membranes from
three distinct structural regions: a region flanking the T-tubules (triadic SR), a SR region across the Z-line (ZSR), and a
longitudinal SR region across the M-line (LSR). Analysis of isolated murine muscles reveals that nanospan is mostly
associated with the ZSR and triadic SR, and only minimally with the LSR. Furthermore, nanospan is absent from the SR
of δ-SG-null (Sgcd−/−) skeletal muscle, a murine model for limb girdle muscular dystrophy 2F. Analysis of skeletal
muscle biopsies from Duchenne muscular dystrophy patients reveals that nanospan is preferentially expressed in type I
(slow) fibers in both control and Duchenne samples. Furthermore, nanospan is significantly reduced in Duchenne
biopsies.
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Conclusions: Alternative splicing of proteins from the SG-SSPN complex produces δ-SG3, microspan, and nanospan
that localize to the ZSR and the triadic SR, where they may play a role in regulating resting calcium levels as supported
by previous studies (Estrada et al., Biochem Biophys Res Commun 340:865–71, 2006). Thus, alternative splicing of SSPN
mRNA generates three protein isoforms (SSPN, microspan, and nanospan) that differ in the number of transmembrane
domains affecting subcellular membrane association into distinct protein complexes.
Keywords: Duchenne muscular dystrophy, Dystrophin, Limb girdle muscular dystrophy, Microspan, Nanospan, Sarcolemma,
Sarcoplasmic reticulum, Sarcospan, Transverse tubule
Background
Integral and peripheral membrane proteins of the
dystrophin-glycoprotein complex, or DGC, function to
provide a physical linkage across the muscle membrane
to connect the extracellular matrix with the F-actin cyto-
skeleton [1, 2]. The core components of the DGC in-
clude dystrophin, sarcoglycans (SGs), sarcospan (SSPN),
dystroglycan (α-, β-DG), and syntrophins [3–7]. The SG
subcomplex of the DGC is comprised of four single-pass
transmembrane glycoproteins, referred to as α-, β-, γ-,
and δ-SG [8]. SSPN, a 25-kDa integral membrane pro-
tein with structural homology to the CD20 superfamily
of proteins that also exhibits some similarities with the
tetraspanins [1], interacts with the SGs at the sarco-
lemma to form a tight subcomplex (SG-SSPN) that an-
chors α-DG to the cell surface and contributes to the
maintenance of cell integrity [9]. Autosomal recessive
limb girdle muscular dystrophy (AR-LGMD) types 2D,
2E, 2C, and 2F are caused by primary mutations in α-,
β-, γ-, and δ-SG genes, respectively. Lack of expression
of any one of the SGs results in specific loss of the entire
SG-SSPN subcomplex, destabilization of α-DG, and
sarcolemma damage [8–10].
While the loss of muscle cell adhesion complexes that
render the sarcolemma susceptible to contraction is
widely accepted as the initial insult to dystrophic muscle,
there is strong support for dysfunctional calcium hand-
ling in muscle fibers that contributes to disease progres-
sion. Electrophysiological studies have revealed impaired
excitation-contraction coupling in dystrophin-deficient
(mdx) muscle, including decreased calcium release from
the sarcoplasmic reticulum (SR) in response to voltage
activation in mdx myofibers [11–14]. Structural and
functional defects in the SR calcium release channel rya-
nodine receptor 1 (RyR1) have contributed to the “leaky”
channel model. Elegant studies from Marks and
colleagues [15–17] have revealed an increase in S-
nitrosylation of cysteine residues of RyR1 in mdx muscle
leading to disruption of RyR1 macrocomplexes (includ-
ing depletion of calstabin1) that regulates calcium
release from the SR [15–17]. Defective mechanotrans-
duction signaling caused by reactive oxygen species
(ROS) contributes to mdx calcium dysfunction in a
mechanism that includes increased sarcolemma calcium
influx through mechanosensitive calcium channels
[18–20]. The relevance of SR function to disease pro-
gression in the dystrophinopathies and sarcoglycanopa-
thies is becoming clear as SERCA1 overexpression in
mdx and δ-SG-null (Sgcd−/−) mice reduces central nu-
cleation, tissue fibrosis, and membrane damage [21].
Furthermore, introduction of SERCA1 reversed SR
calcium reuptake defects and reduced total cytosolic cal-
cium that characterizes dystrophic muscle [21]. These
studies are bolstered by additional reports that introdu-
cing SERCA2 or a dominant-negative Orai1 reduces dys-
trophic pathology by ameliorating SR calcium handling
defects [21, 22].
Using confocal and electron microscopy, Ueda and
colleagues demonstrated that γ- and δ-SG are present in
the SR membranes in addition to their localization with
dystrophin at the sarcolemma while α- and β-SG are
confined to the sarcolemma [23]. This finding suggested
that γ- and δ-SG must have additional functions in the
SR membranes independent of their role in the DGC at
the sarcolemma. Moreover, it was later reported that an
alternatively spliced isoform of δ-SG called δ-SG3, in
which the C-terminus is replaced by 10 amino acids, is
also exclusively expressed at the SR membranes of
skeletal muscle [24]. Based on the location of this protein
and the abnormalities in calcium homeostasis across the
SR membranes previously described in δ-SG-deficient
animals, the authors hypothesize that δ-SG3 could be
involved in the regulation of appropriate localization
and/or maintenance of the proteins participating in
calcium homeostasis in the SR.
We have previously identified an alternatively spliced
isoform of SSPN that is not localized to the sarcolemma
[25]. SSPN messenger RNA (mRNA) undergoes alterna-
tive splicing to generate a novel smaller protein that we
named microspan (μSPN) [25], which is enriched in
both the light and heavy fractions of the SR membrane
(LSR and HSR, respectively) [26]. Analysis of the SR
fractions revealed that while γ-SG, δ-SG, δ-SG3, and
μSPN are all present in the LSR, only δ-SG3 and μSPN
seem to be expressed in the HSR. Furthermore, evalu-
ation of the expression of these proteins in skeletal
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muscle of Sgcd−/− mice showed that loss of δ-SG expres-
sion results in secondary loss of γ-SG and μSPN. The
findings raise the possibility that these proteins may be
associated as a complex in the SR membranes and that
δ-SG (or δ-SG3) may play a role in the stabilization and/
or localization of γ-SG and μSPN expression at the SR
[26]. Assessment of the Ca2+ release and uptake of the
LSR and HSR from wild-type and Sgcd−/− mice showed
that, whereas the Ca2+ release from HSR vesicles from
these mice is not different, Ca2+ efflux (mainly through
SERCA1) is considerably increased in LSR vesicles from
Sgcd−/− mice [26]. In addition, the authors showed mod-
ifications in the thermal stability and enthalpy of
SERCA1 in LSR vesicles from Sgcd−/− mice, suggesting
that absence of the LSR-specific SG-SSPN complex
(γ-SG, δ-SG, δ-SG3, and μSPN) affects the structure and
function of SERCA1 [26].
In the current study, we report the identification of a
third protein generated from alternate splicing of SSPN
mRNA. We designate it “nanospan” or nSPN as the pre-
dicted molecular weight (10.5 kDa) is smaller than that
of either SSPN or μSPN. We demonstrate that nSPN is
localized to the SR membranes and is reduced in the
dystrophic disease context.
Methods
cDNA library screen
A human skeletal muscle complementary DNA (cDNA)
library (BD Biosciences Clontech) was screened with
probes representing SSPN exons 1 and 3, as described
previously [25]. Clones containing exon 1, but not exon
3, were purified and PCR-amplified using primers in the
vector arms. PCR products were cloned into pCR@2.1-
TOPO@ (Invitrogen, Carlsbad, CA) and subjected to
direct DNA sequencing (UCLA Sequencing and Geno-
typing Core Facility). Clones containing exon 1 spliced
to a novel exon, named exon 4, were identified. An open
reading frame was identified and predicted to encode a
small, 10.5-kDa protein that was named nanospan
(abbreviated as nSPN), as depicted (Fig. 1).
As a complementary approach, the nSPN cDNA was
amplified by reverse transcriptase polymerase chain
reaction (RT-PCR) from 2.5 μg of Marathon-Ready™ hu-
man skeletal muscle cDNA (BD Biosciences Clontech,
San Jose, CA) using forward primers in exon 1
(SSPNATGF: 5′-ATGGGCAAGAACGAGCAG-3′; Gen-
Bank AF016028; human SSPN) and reverse primers in
the 3′ untranslated region (UTR) of μSPN located 26
nucleotides (nt) downstream of the stop codon
(Ex3vReverse: 5′-TCCATTCCAAATGGCTTGAT-3′).
Table 1 provides a complete list of PCR primers used
in the study. A second round of PCR was performed
as above using the exon 1 forward primer (SSPNATGF)
and a second, nested reverse primer located between
the boundary of exon 4 with 2 nt in exon 1 (Ex1/4R:
5′-TCAGAAGTCATGACAATGGATAA-3′; GenBank
EU433933; human μSPN). PCR was performed with
an Eppendorf gradient thermocycler (Westbury, NY)
using the following conditions: 35 cycles of denaturation
at 94 °C for 15 s, annealing at 52 °C for 90 s, and extension
at 72 °C for 2 min, followed by 72 °C for 10 min. PCR
products were subjected to agarose gel electrophoresis
and gel extraction with QIAEX II Gel Extraction System
(Qiagen, Valencia, CA). Two PCR products were isolated,
cloned into pCR2.1-TOPO@ and subjected to direct DNA
sequencing (Additional file 1 : Figure S1). One of the
fragments (387 base pairs (bp)) encoded μSPN (NCBI
EU433933), which served as a positive control for the
PCR. A second, smaller fragment (300 bp) represented
direct splicing of exon 1 to exon 4 to create a complete
open reading frame (ORF) with an initiator methionine
and a stop codon (Fig. 1b). The ORF is predicted to en-
code nSPN (Fig. 1c). The NCBI/GenBank accession num-
ber for the human nSPN sequence is DQ897666.
RT-PCR multiple tissue analysis
Total RNA (1 μg) from human tissues was used to
synthesize cDNA using the Promega Reverse Transcrip-
tion System (Promega, Madison, WI). RT-PCR was
performed using a forward primer in exon 1 (SSPN1118F:
5′-CTGCTAGTCAGGGACACTC-3′; GenBank AF016028;
human SSPN) and a reverse primer in the 3′ UTR of nSPN
that is 7 nt downstream of the stop codon (Ex4R: 5′-
TTGATTCTGAGAACATTCTCTTTC-3′; GenBank EU43
3933; human μSPN). Please refer to Table 1 for supporting
oligonucleotide information. RT-PCR conditions were per-
formed as previously described [25, 27].
Northern blotting
Adult human multiple tissue Northern blots (Clontech Inc.)
containing 2 μg of poly-A+ RNA per lane were probed with
oligonucleotides spanning exon 1 and exon 4 as described
previously [1] and in Table 1.
Generation of nSPN antibodies
Polyclonal nSPN antibodies were produced by injecting
500 μg of a synthetic peptide (Peptide 20 CAARRFWA-
GIIIHCHDF, New England Peptide, Gardner, MA)
coupled to KLH into a New Zealand white rabbit (Rabbit
20, Charles River, Wilmington, MA), using previously
described methods [1, 25]. The peptide sequence spans
the junction between exons 1 and 4 (Fig. 1a, double
underline), which is unique to nSPN. Antibodies were
affinity-purified from rabbit serum using nSPN peptides
coupled to BSA and are referred to as R20. Antibodies
to the N-terminal region of SSPN (SSPN amino acid
1–26; GenBank accession number U02487, Rabbit 3) were
previously generated [25]. These antibodies recognize
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SSPN, μSPN, and nSPN as these isoforms all contain the
N-terminal region encoded by exon 1 (Table 2).
Animal models
mdx (C57-BL/10ScSn-Dmdmdx/J), wild-type (C57-BL/
6J), and δ-SG-null (Sgcd−/−, B6.129-Sgcdtm1Mcn/J) mice
were purchased from Jackson Laboratory (Bar Harbor,
ME). SSPN-deficient mice [28] were a gift from Kevin P.
Campbell, Ph.D. (University of Iowa College of Medi-
cine, Howard Hughes Medical Institute, Iowa City, IA)
and are available from Jackson Laboratory. Genotyping
was confirmed through established PCRs as described
previously [29]. Mice were maintained in the Terasaki
Life Sciences Vivarium, and all procedures were performed
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Fig. 1 Alternative splicing of SSPN generates μSPN and nSPN. a A schematic representation of the genomic organization of the SSPN gene on
human chromosome 12p11.2. Exons are depicted as solid boxes and are color-coded. Exon 1 (red), exon 2 (yellow), exon 3 (blue), exon 4 (green),
and the introns (black lines) are depicted. The approximate size of each intron is indicated (kb). The mRNA splicing patterns generating SSPN,
μSPN, and nSPN are also shown. b Predicted membrane topologies for SSPN, μSPN, and nSPN are illustrated in three separate schematic diagrams.
Each polypeptide region is color-coded according to its corresponding exon. SSPN possesses four transmembrane domains (TM1 to TM4), a small
extracellular loop (SEL), and a large extracellular loop (LEL). μSPN contains two transmembrane domains (TM1 and TM2). N- and C-termini of μSPN are
strongly predicted to be intracellular using topology algorithms. nSPN retains the first transmembrane domain of SSPN (TM1) and is predicted to have
an extracellular C-terminus. The predicted molecular weight of each SSPN-related protein is indicated. c The primary and deduced amino acid sequence of
human nSPN is shown in single-letter code. Each exon and its deduced amino acid sequence are color-coded as follows: exon 1 (red) and exon 4 (green).
The open reading frame of nSPN encodes a polypeptide of 99 amino acids. The predicted transmembrane domain (TM1) is underlined. The 12-amino-acid
region used as an antigen for polyclonal antibody (Rabbit 20) production is double-underlined. Arrows indicate forward and reverse primers, summarized in
Table 1, used in RT-PCR analysis (Additional file 1: Figure S1). The asterisk represents the predicted stop codon
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in accordance with guidelines set by the University of
California, Los Angeles Institutional Animal Care and Use
Committee (A3196-01).
Control and DMD protein preparations
Total skeletal muscle lysates were prepared in modified
RIPA lysis buffer (1% Nonidet P-40, 0.5% sodium deoxy-
cholate, 0.1% SDS, 1 mM EDTA, 5 mM N-ethylmaleimide,
50 mM sodium fluoride, 2 mM β-glycerophosphate, 1 mM
sodium orthovanadate, 100 nM okadaic acid, 5 nM micro-
cystin LR, and 20 mM Tris-HCl; pH 7.6). Prior to
homogenization, protease inhibitors (0.6 μg/mL pepstatin
A, 0.5 μg/mL aprotinin, 0.5 μg/mL leupeptin, 0.75 mM
benzamidine, and 0.1 mM PMSF) were added to the lysis
buffer. Samples were rotated at 4 °C for 1 h and clarified by
centrifugation at 15,000 × g for 15 min. Before analysis by
SDS-polyacrylamide gel electrophoresis, protein concentra-
tions were analyzed using the DC Protein Assay® (Bio-Rad,
Hercules, CA). Clarified lysates (60 μg) were loaded onto
15% SDS-polyacrylamide gels and transferred to nitrocellu-
lose (Millipore Corp., Billerica, MA). Nitrocellulose mem-
branes were subsequently incubated with affinity-purified,
polyclonal antibodies to nSPN (Rabbit 20, bleed 2; 1:100)
and SSPN (Rabbit 15, bleed 4; 1:100). Horseradish
peroxidase-conjugated anti-rabbit IgG (Amersham Phar-
macia Biotech, Piscataway, NJ) secondary antibodies were
used at a 1:3000 dilution. Coomassie Plus Protein Assay
Reagent (Pierce, Rockford, IL, USA) was used to confirm
equal loading of control and Duchenne muscular dystrophy
(DMD) tissue lysates.
Immunofluorescence analysis
Transverse (8 μm) sections of control and DMD tissue
were prepared utilizing a Leica CM3050 S cryostat
(Leica Microsystems, Bannockburn, IL). Sections were
blocked with 3% BSA in PBS for 1 h at room
temperature (RT). To confirm genotype of human sam-
ples, dystrophin C-terminal antibodies (VP-D505, Vector
Laboratories Inc.) were used. Dystrophin was detected at
the sarcolemma in control tissue, but was absent in
DMD biopsies. For co-localization experiments, sections
were incubated with antibodies to nSPN (Rabbit 20,
bleed 4; 1:10) and slow myosin heavy chain (VP-M667,
Vector Laboratories Inc.; 1:50) or fast myosin heavy
chain (VP-M665, Vector Laboratories Inc.; 1:25), at 4 °C
for 12 h. After washing, sections were incubated with
FITC anti-rabbit (Vector Laboratories Inc.) and Cy3
anti-mouse (Jackson ImmunoResearch, West Grove, PA)
secondary antibodies diluted 1:500 for 1 h at RT.
Sections were washed with PBS and mounted using
VECTASHIELD (Vector Laboratories Inc.). Sections
were incubated with secondary antibodies alone as a
negative control (data not shown). All sections were
photographed under identical conditions using an Axioplan
2 fluorescence microscope and AxioVision 3.0 software
(Carl Zeiss Inc, Thornwood, NY).
Table 1 RT-PCR primers for SSPN, μSPN, and nSPN amplification
Primer name Sequence (5′➔ 3′) NCBI accession no. Usage Location within SSPN Cross-reactivity Species
SSPNATGF ATGGGCAAGAACGAGCAG AF016028 Forward primer, 1st and
2nd PCR
Exon 1 SSPN, μSPN,
and nSPN
Human
Ex3vReverse TCCATTCCAAATGGCTTGAT EU433933 Reverse primer, 1st PCR 3′ UTR
(26 nt downstream
of stop codon)
μSPN, nSPN Human
Ex1/4R TCAGAAGTCATGACAATGGATAA EU433933 Reverse primer, 2nd PCR;
probe, Northern blot
Exon 1 and exon
4 boundary
μSPN, nSPN Human
SSPN118F CTGCTAGTCAGGGACACTC AF016028 Forward primer, RT-PCR Exon 1 SSPN, μSPN,
and nSPN
Human
Ex4R TTGATTCTGAGAACATTCTCTTTC EU433933 Reverse primer, RT-PCR 3′ UTR
(7 nt from stop codon)
μSPN, nSPN Human
Table 2 Rabbit polyclonal antibodies to SSPN, μSPN, and nSPN
Antibody
(Rabbit #)
Antigen Location (amino acid region) Species cross-reactivity Protein cross-reactivity
3 GST-mouse N-terminal fusion protein 1–26 Mouse SSPN, μSPN, and nSPN
12 and 13 Human C-terminal peptide 117–128 Human, mouse, rabbit μSPN
14 Rabbit N-terminal peptide 4–20 Rabbit SSPN, μSPN, and nSPN
15 Human N-terminal peptide 4–26 Human SSPN, μSPN, and nSPN
18 Mouse MBP C-terminal fusion protein 186–216 Mouse SSPN
20 Human C-terminal peptide 88–99 Human, mouse, rabbit nSPN
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Isolation of transverse tubular and sarcoplasmic reticulum
membranes
Transverse tubules (T-tubules) and SR membranes were
obtained from total skeletal muscles dissected from
4-month-old wild-type (WT) and Sgcd−/− mice. Isolation
was performed by differential centrifugation and a dis-
continuous sucrose gradient as previously described
[30]. Membrane isolation was performed in the absence
of any reducing agent in the buffer medium. The micro-
somal fraction was placed in a first sucrose gradient of
25, 27.5, and 35% (w/v). The 25/27.5% interface showed
the maximal signal for DHPR as determined by im-
munoblotting, indicating that the microsomal fraction
contains T-tubule membranes (not shown). An add-
itional centrifugation through a 25/45% discontinuous
sucrose gradient was done to remove Ca2+-oxalate-
loaded vesicles [31]. Heavy SR and light SR were isolated
from the 35% band obtained from the first discontinuous
sucrose gradient essentially as previously described [32].
Light SR was detected by the maximum ATPase activity
stimulated by Ca2+, and HSR was detected by the max-
imal immunoreactivity with the antibody anti-RyR. Anti-
nSPN antibodies were used for immunoblot analysis
(R20, B2). Membrane preparations were validated by
immunoblot analysis with antibodies to DHPR, RyR,
SERCA1, and triadin (data not shown) as described pre-
viously [30, 31]. Protein concentration was determined
using Coomassie Plus Protein Assay Reagent (Pierce,
Rockford, IL, USA) with BSA as the standard.
Mouse muscle immunohistochemistry
Flexor digitorum brevis and interosseous muscles were
dissected from C57-BL/6J and SSPN-null mice. Muscles
were slightly stretched and pinned down into a Sylgard-
bottomed petri dish containing Tyrode’s solution
(145 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2,
10 mM Na-MOPS, and 10 mM dextrose; pH 7.2). Sur-
rounding connective tissue was mechanically removed
under a dissecting microscope. Subsequently, muscles
were fixed in 2% paraformaldehyde (in Tyrode’s) for
1.5 h at RT. After three washes with PBS (10 min each),
muscles were permeabilized (0.2% Triton X-100, 1% FBS
in PBS) for 1.5 h at RT, and then washed three times
with a 1% FBS solution in PBS (10 min each). When pri-
mary antibodies raised in mice were utilized, an extra
blocking step was added to the protocol at this point, by
employing a Mouse on Mouse (M.O.M.™) basic kit
(Vector Laboratories Inc.), following the manufacturer’s
instructions. Muscles were then incubated with the pri-
mary antibody (diluted in either M.O.M. diluent or 1%
FBS in PBS) for 6 h at RT or overnight at 4 °C. After
three washes (1% FBS in PBS, 10 min each), muscles
were later incubated in the correspondent secondary
antibody, labeled with either Alexa 488 or Texas Red
(diluted 1:50 either in M.O.M. diluent or 1% FBS in
PBS) for 6 h at RT or overnight at 4 °C. Samples were
finally washed three times with PBS (10 min each) and
then maintained in PBS until imaged. Sequential, not
simultaneous, labeling was used when two different anti-
bodies were used.
Two-photon laser scanning microscopy
Antibody-labeled muscles were pinned down on Sylgard-
bottomed petri dishes containing PBS and placed on the
stage of an upright microscope (BX51WI, Olympus,
Japan) equipped with a tunable Chameleon Ti/Sapphire
laser (Coherent) and a Radiance 2000 Scanning Head
(Bio-Rad, UK). Images were acquired with a ×20, 0.95 NA
(Olympus XLUMPLANFL) water-immersion objective.
Muscles labeled with Alexa 488 alone or Alexa 488 and
Texas Red were excited with a laser wavelength of
840 nm. Images were simultaneously acquired using the
following filter combinations (band-pass/dichroic/band-
pass, in nm): second harmonic generation (SHG) and
Alexa 488 emission (410-490//495//500-530), Alexa 488
and Texas Red emission (500-530//550//620-660), and
SHG and Texas Red emission (402-446//495//615-645).
Images were analyzed using commercial (LaserSharp
2000, Bio-Rad, UK) and/or public-domain image analysis
software package (ImageJ).
Results
Molecular cloning of nanospan, a splice variant of sarcospan
The SSPN gene is located on human chromosome
12p11.2 and consists of four exons separated by large in-
trons [1, 33]. The full-length SSPN protein is encoded
by three small exons (exons 1, 2, and 3) specifying a 25-
kDa protein with four membrane-spanning domains
(TM1–4 from the N- to the C-terminus), a short extra-
cellular loop (SEL), and a large extracellular loop (LEL;
Fig. 1a, b) [1]. The N- and C-termini are predicted to be
intracellular. We have shown that SSPN mRNA under-
goes alternative splicing to generate microspan (μSPN)
[25]. Exons 1, 2, and 4 encode μSPN, a 14-kDa protein
that is predicted to contain an intracellular N-terminus
as well as transmembrane domains 1 and 2 (Fig. 1b;
amino acids encoded by exons 1 and 2 are in red and
yellow, respectively). Exon 4 introduces six new amino
acids that are predicted to be intracellular (Fig. 1b;
amino acids encoded by exon 4 are in green). μSPN is
not present at the sarcolemma, but is localized within
the SR membranes [25].
The presence of multiple SSPN-related transcripts that
encode alternately spliced isoforms of SSPN is supported
by Northern blot analysis in which many SSPN tran-
scripts are present in skeletal and cardiac muscle [1, 33].
All transcripts hybridized to SSPN exon 1 probes, sug-
gesting that exon 1 is common to all SSPN isoforms,
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while exon 3 probes only hybridized to a single band on
Northern blots [1, 33]. In our original identification of
μSPN, we screened a human skeletal muscle cDNA
library separately with exon 1 and exon 3 probes. We
identified many clones that hybridized to exon 1, but
not exon 3, suggesting the presence of other SSPN-
related transcripts. As previously reported [25], four
individual clones were isolated with inserts of approxi-
mately 4 kb, and one of these clones contained an SSPN
splice variant that we named μSPN. In the current study,
we report on the DNA sequencing of a second clone, re-
vealing the presence of an ORF flanked by a short 5′
UTR and a long 3′ UTR. The ORF was composed of
exon 1 spliced to exon 4 (GenBank DQ897666; Fig. 1).
As a complementary approach, RT-PCR amplification
was performed using human skeletal muscle cDNA as a
template. The forward primer was designed to hybridize
to exon 1, which is common to both SSPN and μSPN
(Fig. 1c). However, the reverse primer sequence hybrid-
ized to exon 4, which is unique to μSPN (Fig. 1c). PCR
assays performed with primers in exons 1 and 4 are pre-
dicted to amplify μSPN as well as any other cDNAs hy-
bridizing to the exon 1 and 4 primers. Only two PCR
products were isolated and characterized by direct DNA
sequencing (Additional file 1: Figure S1). One of the
fragments (387 bp) encoded μSPN (NCBI EU433933),
which served as a positive control for the PCR. A sec-
ond, smaller fragment (300 bp) represented direct spli-
cing of exon 1 to exon 4 to create a complete ORF with
an initiator methionine and a stop codon (Fig. 1b). The
ORF is predicted to encode a polypeptide of 99 amino
acids with a calculated molecular weight of 10.5 kDa
(Fig. 1c; NCBI DQ897666). We designate this isoform as
“nanospan” (nSPN), in keeping with prior nomenclature
reflecting the predicted molecular weight of SSPN
isoforms (Fig. 1).
SSPN exhibits homology to the CD20 and tetraspanin
superfamilies. Topology algorithms predict the N- and
C-termini of SSPN are both intracellular, as illustrated in
Fig. 1b [1]. μSPN is encoded by splicing of exons 1, 2,
and 4 to produce a protein with only two transmem-
brane domains (TM1–2) likely forming a hairpin loop
structure in the plasma membrane [25]. The primary
amino acid sequence deduced from the human cDNA of
nSPN predicts a protein with a single membrane-
spanning domain and a topology distinct from either
SSPN or μSPN (Fig. 1c). Exon 1, common to all three
splice variants of SSPN, encodes an intracellular N-
terminus and one transmembrane domain (Fig. 1a–c;
amino acids encoded by exon 1 are in red). In nSPN,
exon 1 is directly spliced to exon 4, which encodes only
six amino acids followed by a stop codon (coded in
green). Although nSPN and μSPN both contain exon 4,
their C-terminal regions are predicted to lie on different
faces of the membrane. nSPN does not have homology
to any other known proteins found in the GenBank,
TIGR, or dbEST databases and does not possess con-
served sites for glycosylation. TM3, LEL, and TM4 are
unique to SSPN, and previous work from our group
suggests the major SG binding domain(s) is within
LEL [34]. This is consistent with previous data that
SSPN, but not μSPN, is an integral component of the
DGC [1, 33, 35].
Nanospan mRNA is expressed in human skeletal muscle
To examine the distribution of nSPN mRNA, Northern
blot analysis was performed on a broad range of human
tissues. Nylon membranes containing poly-A+ RNA were
probed with oligonucleotides designed to hybridize to
nSPN (Table 1), as illustrated in Fig. 1a. We observed an
abundant 1.5-kb transcript in heart, liver, and skeletal
muscle (Fig. 2). Lower levels of the 1.5-kb nSPN tran-
script were found in several non-muscle tissues includ-
ing the brain, placenta, kidney, and pancreas. RT-PCR
analysis on cDNA isolated from a variety of human
tissues demonstrates nSPN is highly expressed in stri-
ated muscles (Additional file 1: Figure S1), supporting
Northern blot data.
Detection of nanospan protein in skeletal muscle
In order to assess the expression nSPN at the protein
level, we generated polyclonal antibodies against nSPN
by immunizing rabbits with a 12-amino-acid synthetic
peptide. The peptide sequence was chosen to span the
junction between exon 1 and exon 4, which includes six
amino acids encoded by each exon (Fig. 1c, double
9.5 - 
7.5 - 
4.4 - 
2.4 - 
1.35 - 
0.24 - 
nSPN
Fig. 2 Expression of nSPN mRNA transcript in human tissues. Northern
blots containing 2 mg of poly-A+ RNA from the indicated human tissues
were hybridized with nSPN-specific oligonucleotide. An arrow indicates
the 1.5-kb nSPN mRNA transcript. Molecular size markers are indicated
on the left (kb)
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underline). Specificity of nSPN antibodies was deter-
mined using multiple assays. First, we demonstrate that
affinity-purified R20 antibodies only recognized BSA
coupled to nSPN Peptide 20 and do not cross-react with
BSA conjugated to non-specific peptide or to BSA alone
(Fig. 3a). Second, the specificity of R20 was investigated
using peptide competition experiments, as previously
described [1, 25]. R20 antibodies recognized nSPN
(~11 kDa) in microsomes prepared from rabbit and
mouse skeletal muscles (Fig. 3b). We found that R20
binding to nSPN was inhibited in the presence of nSPN
Peptide 20 (Fig. 3c), but not in the presence of a non-
specific control peptide (Fig. 3d). Lastly, we demonstrate
that nSPN antibodies do not cross-react with μSPN by
probing protein lysates from wild-type (non-transgenic)
and μSPN-transgenic (Tg) skeletal muscle. μSPN-specific
antibodies (Rabbit 12 [22]) bind to the μSPN-Tg protein
(Fig. 3e). However, nSPN antibodies do not cross-react
with μSPN (Fig. 3e). To demonstrate that nSPN anti-
bodies do not cross-react with SSPN, we probed protein
lysates from wild-type (non-transgenic) and SSPN-Tg
skeletal muscle. SSPN-specific antibodies (Rabbit 15 [21])
bind to the SSPN-Tg protein (Fig. 3f). However, nSPN
antibodies do not cross-react with SSPN (Fig. 3f). We
used transgenic overexpression models for these experi-
ments due to the abundance of μSPN and SSPN that is
amenable to robust protein detection.
Analysis of membrane fractions reveals that nSPN is enriched
in SR and is lost in δ-SG nulls
Affinity-purified antibodies were used to investigate
nSPN expression in preparations of skeletal muscle
membranes. Specifically, T-tubule, light SR, and heavy
SR membranes from skeletal muscle of wild-type mice
were isolated by sucrose gradient ultracentrifugation, as
previously described [26]. The T-tubule membranes are
invaginations of the sarcolemma that contain a large
number of L-type calcium channels (DHPR). SR mem-
branes are biochemically segregated into two functional
domains, a longitudinal region (light SR) with SERCA1
enrichment and a triadic (heavy) region (heavy SR) com-
posed of terminal cisternae, which are adjacent to each
T-tubule and contain proteins such as RyR, triadin, and
calsequestrin [36]. Immunoblot analysis of these frac-
tions reveals that nSPN is not present in T-tubule mem-
brane preparations, but is very abundant in heavy SR
membranes, while low levels of nSPN are detectable in
light SR (Fig. 4a–c). As controls, DHPR, RyR, and
SERCA are shown.
It is well established that SSPN interacts with the SGs
at the sarcolemma [9, 34, 37] and that μSPN interacts
with a variation in the SGs in the SR [25, 26]. In these
experiments, both SSPN and μSPN are lost in multiple
SG-deficient mouse models [38–40]. We recently dem-
onstrated that loss of SSPN in SSPN-null skeletal and
heart muscles significantly decreases abundance of the
SGs leading to reduced strength [41, 42]. In order to de-
termine whether nSPN is affected by loss of the SGs, we
analyzed purified T-tubule, light SR, and heavy SR frac-
tions from skeletal muscle of Sgcd−/− mice. Loss of δ-SG
leads to the complete absence of the other SGs [43], and
we did not detect any SG contamination in the prepara-
tions (data not shown). Previous studies have shown that
γ-SG, δ-SG, δ-SG3, and μSPN are present in the light SR
nSPN (R20) Ab
nSPN (R20) Ab +  
Non-Specific Peptide 
nSPN (R20) Ab +  
nSPN Peptide 
B 
C 
D 
A
60-  
148 - 
250 - 
nSPN (R20) Ab E µSPN
(R12) Ab
nSPN
(R20) Ab
17 - 
22 - 
SSPN   
(R15) Ab
22 -  
30 -  
42 -  
nSPN
(R20) Ab
F 
Fig. 3 Expression of nSPN protein in skeletal muscle from multiple
sources. Immunoblots containing BSA alone, BSA coupled to nSPN
(BSA-nSPN), and BSA coupled to nSPN-specific Peptide 20 (BSA-nSPN) (a).
R20 antibodies recognized an ~11-kDa protein band on immunoblots of
total microsomes prepared from mouse and rabbit skeletal muscles
(b–d). Binding of R20 antibodies (R20 Ab) to nSPN was inhibited by nSPN
peptides (c), but not by non-specific control peptides (d). Nitrocellulose
membranes of protein lysates from wild-type (non-transgenic) and
μSPN-transgenic (Tg) skeletal muscle were probed with μSPN-specific
antibodies (R12), which demonstrate cross-reactivity to μSPN-transgenic
protein as expected (e). However, nSPN antibodies do not cross-react
with μSPN (e). Total protein lysates from wild-type (non-transgenic) and
SSPN-Tg skeletal muscle were probed with SSPN-specific antibodies
(R15) that cross-react with SSPN, as expected (f). However, nSPN
antibodies (R20) do not cross-react with SSPN (e). Table 2 summarizes
antibodies used in the study. Molecular weight markers (kDa) are provided
on the left
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of control mice, but are absent in the light SR of Sgcd−/−
mice [26]. Additionally, our previous analysis using iden-
tical preparations demonstrated that δ-SG3 and μSPN
are enriched in the heavy SR of wild-type muscle, but
are lost in the heavy SR of the Sgcd−/− mice. We found
that nSPN was diminished or absent from heavy SR and
light SR fractions in the Sgcd−/− samples, respectively
(Fig. 4a–c). These data suggest that nSPN’s localization
to the SR may be dependent on δ-SG, where it has the
potential to form a subcomplex with the other SGs and
μSPN. It is also feasible that nSPN is lost as a secondary
consequence of the disease process, and additional ex-
periments will be needed to distinguish between these
possibilities.
Subcellular localization of nanospan
To more precisely localize nSPN within the SR, we used
two-photon laser scanning microscopy (TPLSM) to
image wild-type flexor digitorum brevis and interosseous
muscles labeled with nSPN antibodies and visualized by
indirect immunofluorescence. Three regions of SR mem-
branes have been defined based on evidence from elec-
tron microscopy [44–46]: a triadic region flanking the
T-tubules (triadic SR), an SR region across the Z-line
(ZSR; [45]), and an SR region across the M-line (LSR;
[45]). Note that both the ZSR and LSR are represented
in light SR fractions, while the triadic SR is represented
in the heavy SR fractions in biochemically isolated mem-
branes from skeletal muscle. The precise position of
nSPN with respect to sarcomere structures was deter-
mined based on its relative distribution against two land-
marks of the sarcomere: (i) the A-band centered at the
M-lines, indicated by the fluorescence generated by SHG
[47], and (ii) the Z-lines, indicated by labeling with α-
actinin-specific antibodies. The data in Fig. 5 reveal the
location of nSPN in stretched fibers relative to the fluor-
escence intensity from α-actinin antibodies and SHG
fluorescence signal.
As shown in the TPLSM images and highlighted in the
intensity profiles of Fig. 5, nSPN is distributed in alter-
nating bands within slightly stretched fibers (~3 μm)
from WT mice. One band is relatively thicker and
brighter, displaying two peaks, and the alternate band is
thinner and fainter, displaying a single peak. As ex-
pected, α-actinin (red) is visualized as thin, sharp trans-
versal bands (Fig. 5b). The overlay image in Fig. 5c and
the profiles in Fig. 5g demonstrate that the two peaks of
the wide band of nSPN are centered on the α-actinin
band (i.e., the Z-line, also Additional file 2: Figure S2
A–C and G), while the single-peaked band localizes half-
way between two consecutive α-actinin bands. A similar
result was obtained in another muscle in which the
localization of nSPN (Fig. 5d) is compared with the maxima
of SHG images (Fig. 5e). In this case, both the overlay image
 nSPN
 RyR
 DHPR
 nSPN
  WT       Sgcd 
A
C
B
 SERCA1
 nSPN
  WT       Sgcd 
  WT       Sgcd 
T-tubules 
Light SR 
Heavy SR 
250- 
98- 
148- 
250- 
130- 
6- 
16- 
6- 
16- 
6- 
16- 
Fig. 4 Analysis of nSPN in isolated T-tubule and sarcoplasmic reticulum
membranes. T-tubule sarcoplasmic reticulum (SR) membranes were
prepared from skeletal muscle from control wild-type (WT) and δ-SG-null
(Sgcd) mice. Samples analyzed include T-tubules (a), light SR (b), and
heavy SR (c). Immunoblotting of DHPR, SERCA1, and RyR in different
fractions of muscle microsomes after sucrose gradient centrifugation to
separate T-tubule and SR fractions. Previous studies have shown that
γ-SG, δ-SG, δ-SG3, and μSPN are present in the light SR of control mice,
but are absent in the light SR of δ-SG-null mice [26]. Additionally, our
previous analysis using identical preparations demonstrated δ-SG3 and
μSPN are enriched in the heavy SR of wild-type muscle, but are lost in
the heavy SR of the δ-SG-null mice. Molecular weight markers (kDa) are
provided on the left
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(Fig. 5f) and the intensity profile (Fig. 5h) demonstrate that
there is minimal nSPN expression at the SHG peak (i.e., the
M-line) and that the double-peaked band is located midway
between two consecutive SHG maxima (i.e., the Z-line).
The schematics of the sarcomere in Fig. 5g, h illustrate the
position of nSPN with respect to contractile hallmarks.
TPLSM images from WT muscles that are slightly more
stretched (~3.7 μm) showed a similar nSPN distribu-
tion except for the fact that the thinner and fainter
band that co-localizes with the SHG maxima is lost
in these images (Additional file 2: Figure S2). This
last result indicates that the nSPN signal centered at
the M-line becomes reduced below the detection level
in the more stretched muscle fibers.
The fluorescence patterns observed in the muscle
fibers with nSPN labeling resemble those observed with
other SR transmembrane proteins such as SERCA and
IP3R (Fig. 6a–c and Fig. 6d–f, respectively). SERCA and
IP3R have been previously shown by immunohistochem-
istry to be expressed in both the SR centered at the Z-
line (ZSR) and the SR centered at the M-line (LSR) [48].
On the other hand, immunolocalization of proteins
expressed only at the triadic junctions such as αDHPR
and RyR1 always displays a double-banding pattern
flanking the Z-line (Fig. 6g–i and Fig. 6j–l, respectively).
In these images, note the shorter distance across the
Z-line than that across the M-line. Taken together,
results from biochemical isolation of skeletal muscle
M M M 
Z Z Z 
M M M 
Z Z Z 
A B C 
G H 
D E F 
nSPN
nSPN SHG Merge 
Merge -actinin
nSPN vs -actinin nSPN vs SHG 
Fig. 5 Nanospan localization is consistent with triad localization in mildly stretched skeletal muscle fibers. TPLSM study of nSPN localization in
stretched FDB skeletal muscle fibers from wild-type (C57-BL/6J) mice. a, b TPLSM images of an FDB muscle simultaneously labeled with nSPN
(Alexa 488) and α-actinin (Texas Red) antibodies, respectively. c The superposition of the images on a and b. d, e Simultaneous TPLSM images
of immunolocalization of nSPN and the SHG obtained from an FDB muscle labeled with an antibody against nSPN (Alexa 488), respectively. f The
superposition of the images on d and e. g The superposition of the Alexa 488 (nSPN, green trace) and Texas Red (α-actinin, red trace) fluorescence
plot profiles of the fibers shown in a–c. h The superposition of the Alexa 488 emission (nSPN, green trace) and SHG (blue trace) profiles of the fibers
shown in d–f (profiles taken from areas indicated with boxes). The schematic diagrams at the bottom of g and h show the correspondence of the
intensity profiles with main sarcomeric hallmarks. Sarcomeric length of the fibers presented in this figure is ~3 μm. Scale bar, 10 μm
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Fig. 6 (See legend on next page.)
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membranes and TPLSM demonstrate that nSPN is
expressed in the SR. Moreover, TPLSM reveals that
nSPN is differentially expressed in the SR membrane,
being more highly expressed in the SR centered at the
Z-line (both in the ZSR and triadic SR) and less highly
expressed in the SR centered at the M-line (thinner and
fainter bands in the immunofluorescence images).
We next addressed the question of whether nSPN can
be detected in fibers from SSPN-null mice, which were
generated by targeted knockout of exon 2, intron 2, and
part of exon 3 [28]. In co-localization experiments, we
found that nSPN is expressed in SSPN-null mice and
that the distribution pattern of nSPN is similar to the
pattern that we documented in wild-type muscle at
similar sarcomere lengths (compare Fig. 7a–c with
Fig. 7d–f ). Moreover, when we compared detailed stain-
ing patterns of muscle fibers from wild-type and SSPN-
null muscles labeled with SSPN antibodies, we were able
to distinguish between cell surface expression and intra-
cellular SR membrane expression. Note that SSPN anti-
bodies were generated to a peptide located within exon
1, which is common to all three isoforms of SSPN. Exon
2 and part of exon 3 were targeted for deletion in the
SSPN-deficient mice [28], which is predicted to disrupt
SSPN and μSPN, but not nSPN expression. SSPN was
not detected at the sarcolemma of SSPN-deficient fibers
(Fig. 7h), as expected and shown previously [28]. Immu-
noblot analysis of protein lysates using nSPN-specific
antibodies revealed increased abundance of nSPN in
SSPN-deficient muscle (Additional file 3: Figure S3).
This raises the possibility that nSPN may compensate
for SSPN within the DGC of SSPN-deficient muscle. To
investigate this possibility, we purified the DGC from
SSPN-deficient muscle with the rationale that inter-
action with the DGC is required in order to compensate
for SSPN. However, nSPN did not co-purify with the
DGC complex in either wild-type or SSPN-deficient
muscles (Additional file 3: Figure S3). These results re-
veal that overall nSPN protein abundance is increased
and localized to the sarcolemma in a heterogeneous
fashion in the context of SSPN deficiency.
Exon 3, encoding transmembrane domains 3 and 4 in
SSPN, is absent in nSPN and μSPN. Through immuno-
fluorescence analysis, we have observed that SSPN is the
only isoform to localize to the sarcolemmal membrane
in wild-type muscle, while nSPN and μSPN localize to
internal SR membranes. These data suggest that protein
regions encoded by exon 3, which include transmem-
brane domains 3 and 4, the large extracellular loop, and
the intracellular C-terminus, are responsible for cell sur-
face localization. In support of this, our prior analysis of
deletion mutants identified regions in the large extra-
cellular loop that interact with the intact, tetrameric
(α-, β-, γ-, δ-SG) subcomplex [9, 34, 37].
Nanospan is enriched in type I muscle fibers and reduced
in DMD
Several forms of muscular dystrophy are caused by gen-
etic mutations in genes encoding protein components of
the DGC. Duchenne muscular dystrophy (DMD) is
caused by mutations in the dystrophin gene resulting in
progressive muscle wasting and weakness [49]. Dys-
trophin and the other DGC components are lost from
the sarcolemma in muscle from DMD patients. Using
affinity-purified nSPN antibodies, we examined nSPN
expression in muscle from DMD patients by immuno-
blot analysis and indirect immunofluorescence. We ex-
amined several DMD patients with primary mutations in
dystrophin and no detectable dystrophin protein. Indir-
ect immunofluorescence assays with antibodies against
the C-terminus of dystrophin verify dystrophin is com-
pletely absent from the DMD sarcolemma (data not
shown). Without dystrophin, the DGC is reduced, likely
the result of rapid protein degradation. Skeletal muscle
cryosections from normal and DMD patients were
examined for nSPN expression by indirect immunofluor-
escence. In transverse sections, we observed an intracel-
lular staining pattern for nSPN in some, but not all,
fibers in normal human skeletal muscle biopsies (Fig. 8a),
suggesting fiber type-specific expression. In co-staining
experiments with slow (type I) and fast (type II) myosin
heavy chain (MHC) antibodies, we found that nSPN
expression is limited to slow-twitch muscle fibers in
normal healthy controls (Fig. 8a). Similarly, nSPN is ro-
bustly expressed in slow fibers from DMD patients
(Fig. 8b). Immunoblot analysis reveals a dramatic de-
crease in nSPN levels in DMD protein lysates relative to
controls. This may be due to the decreased abundance
of slow fibers in the DMD samples (Fig. 8c). We now
show that μSPN protein is dramatically decreased in
(See figure on previous page.)
Fig. 6 Immunolocalization of muscle proteins using two-photon laser scanning microscopy. Two-photon laser scanning microscopy (TPLSM) was
used to study the localization of DHPR, RYR-1, SERCA, and IP3R expression in skeletal muscle fibers from wild-type (C57-BL/6J) mice. b, e, h, k TPLSM
images of the SHG signals obtained simultaneously to the fluorescent signal from fibers labeled with antibodies against SERCA (a, Texas Red), IP3R
(d, Texas Red), DHPR (g, Texas Red), and RyR-1 (j, Texas Red). c, f, i, l The superposition of the images of the Texas Red fluorescence and SHG signals
obtained from the different muscles. m The superposition of the Texas Red and SHG fluorescence plot profiles of the fiber shown in j–l and the relative
localization of the RyR-1 expression in the sarcomere. n The superposition of the Texas Red and SHG fluorescence plot profiles of the fiber shown in
d–f and the relative localization of the IP3R expression in the sarcomere. Scale bar, 10 μm
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DMD muscle protein lysate samples using immunoblot
analysis (Fig. 8c). Similarly, nSPN expression was re-
duced in DMD muscle lysates when compared to nor-
mal controls (Fig. 8c). The blots of μSPN and nSPN in
control and DMD are from identical exposures with an
antibody that cross-reacts with both proteins (Fig. 8c).
These data suggest that nSPN and μSPN are in relatively
equal quantities in control human skeletal muscle.
Discussion
In the current study, we report the isolation of nSPN, an
alternatively spliced isoform of SSPN. nSPN possesses
only one TM domain and is localized to the SR. More-
over, nSPN expression is enriched in the region of the
SR centered at the Z-line, the ZSR, and the triadic SR,
while minimally present in the LSR region of the SR
centered at the M-line (Fig. 9). In fact, nSPN is not
retained by sWGA chromatography, the first step in
DGC purification, suggesting that it does not associate
with proteins containing O-GlcNAc modification. Thus,
nSPN is separated from the DGC during an early frac-
tionation step. Taken together, these data demonstrate
nSPN is not an integral component of the DGC that is
present at the sarcolemma.
We have identified two proteins produced from alter-
natively splicing of SSPN mRNA designated as micro-
span (μSPN) [25] and nanospan (nSPN) (this paper).
SSPN, μSPN, and nSPN each have the same first trans-
membrane domain that is encoded by exon 1. μSPN and
nSPN lack transmembrane domains 3 and 4 as well as
the large extracellular loop (LEL) that is specific to
SSPN. Neither μSPN nor nSPN is associated with the
DGC at the sarcolemma, suggesting that their func-
tions are entirely distinct from those of SSPN, sug-
gesting that the domains unique to SSPN (i.e., TM3,
TM4, and the LEL) may contain the sarcolemma-
targeting domain(s) (Fig. 9). μSPN is localized to the
SR, and we have shown overexpression of μSPN
causes severe disruption of triad development in skel-
etal muscle of transgenic mice [25].
A B C 
D E F 
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R3 Merge SHG 
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SSPN-/- SSPN-/- SSPN-/- 
WT SSPN-/- 
Fig. 7 Full-length SSPN is expressed only in the surface membrane and loss of SSPN does not affect nSPN localization. a–c Simultaneous TPLSM
images of immunolocalization of SSPN, μSPN, nSPN (a) and SHG (b) obtained from an FDB muscle isolated from wild-type mice and labeled with
affinity-purified Rabbit 3 (R3) polyclonal antibodies that recognize an N-terminal region that is common to all three SSPN isoforms (Alexa 488).
c The superposition of the images on a and b. d–f Simultaneous TPLSM images of immunolocalization of nSPN (d) and SHG (e) obtained from
an FDB muscle isolated from SSPN-null mice and labeled with Rabbit 3 (R3) polyclonal antibodies (Alexa 488). Note that exon 2 and part of exon
3 were targeted for deletion in the SSPN nulls [28], which disrupts SSPN and μSPN, but not nSPN, expression. f The superposition of the images
on d and e. g A magnified view of the area enclosed by the white rectangle in c. h A magnified view of the area enclosed by the white rectangle
in f. White arrows in g and h point to the presence (g) or absence (h) of sarcolemmal labeling in the wild-type and SSPN-null mice, respectively.
Sarcomere length ~3 μm. Scale bar, 10 μm
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Several components of the DGC have been localized
to intracellular membrane structures in skeletal muscle.
Ueda and colleagues have reported the expression of
both δ- and γ-SG to the SR in addition to their well-
established localization to the sarcolemma [23]. Interest-
ingly, a splice variant of δ-SG (δ-SG3) localizes to the SR
was identified by the research group of Coral-Vázquez
[26]. δ-SG3 lacks 122 C-terminal amino acids of full-
length δ-SG, including the conserved Cys-rich extracel-
lular domain. The C-terminus of δ-SG3 consists of 10
amino acids, which are encoded by a newly identified
exon 5b [26, 50]. While we demonstrate protein expression
of nSPN, μSPN, and SG isoforms in the SR, it is unclear
whether these proteins form a subcomplex within these
intracellular membrane structures. Given the tight bio-
chemical association of the SG-SSPN complex at the sarco-
lemma, it is feasible that a variation in the SG-SSPN
subcomplex is present in the SR of striated muscle. Further-
more, the identification of several splice variants that
localize exclusively to the SR suggests that these proteins
may function in Ca2+ regulation (Fig. 9). This hypothesis is
further strengthened by the observation that both the mur-
ine and hamster models of δ-SG deficiency display aberrant
intracellular Ca2+ handling in skeletal muscle [26, 50, 51].
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Fig. 8 nSPN exhibits fiber type-specific expression in human skeletal muscle. a, b Localization of nSPN in skeletal muscle biopsies taken from control human
(a) and DMD patients (b). Transverse muscle cryosections (8 μm) were stained with affinity-purified antibodies to nSPN (Rabbit 20) and detected using FITC
(green). In order to determine whether nSPN is preferentially expressed in either fast- or slow-twitch muscle, sections were co-stained with MHCfast and
MHCslow, as indicated. nSPN is preferentially expressed in intracellular membrane compartments within slow-twitch muscle. Merged images are shown in
right panels. Scale bar, 20 μm. c Skeletal muscle lysates from normal control and DMD biopsies were analyzed by SDS-polyacrylamide gel electrophoresis and
immunoblotted using antibodies recognizing SSPN, μSPN, and nSPN. Protein expression levels of SSPN and μSPN are dramatically reduced in DMD muscle
lysates. nSPN is only moderately reduced in DMD samples. Coomassie blue (CB)-stained protein gels are shown as loading controls. Molecular weight markers
(kDa) are provided on the left
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Future studies will focus on determining whether the SG-
SSPN isoforms that are localized to the SR truly form a
subcomplex and whether perturbations in the complex
affect intracellular Ca2+ levels.
Conclusions
 In the present work, we identify nSPN as an alternatively
spliced isoform of SSPN that is generated from the
splicing of exon 1 to exon 4. Exon 4 encodes six amino
acids. nSPN is predicted to contain only one
transmembrane domain, so that the N- and C-
terminal regions are on the luminal and cytosolic
faces of the membrane, respectively.
 Analysis of gene expression reveals that nSPN is
enriched in skeletal and cardiac muscles.
 Using multiple approaches including biochemical
fractionation and TPLSM, we demonstrate that nSPN
is localized to specific structures at the SR membranes,
particularly enriched at the ZSR and the triadic SR, and
much less highly expressed at the LSR regions centered
at the M-line, as illustrated in Fig. 9.
 Loss of SSPN and μSPN by targeted deletion of exon
2, intron 2, and exon 3 does not affect localization of
nSPN to the SR, but SSPN deficiency does lead to
increased abundance of nSPN that does not associate
with the DGC.
 nSPN expression is lost in muscle from Sgcd−/− mice,
a model for limb girdle muscular dystrophy type 2F.
 In human muscle biopsies, nSPN expression is
restricted to slow muscle fibers. nSPN expression is
reduced, but not absent, in skeletal muscle from
Duchenne muscular dystrophy cases.
 In summary, alternative splicing of SSPN mRNA
generates three protein isoforms (SSPN, μSPN, and
nSPN) that differ in the number of transmembrane
domains affecting subcellular membrane association
into distinct protein complexes.
Fig. 9 Alternative splicing produces SSPN, μSPN, and nSPN with distinct subcellular membrane localizations. The schematic diagram illustrates the
sarcolemma, SR, and T-tubule membranes and their placement with respect to the muscle sarcomere. The SR has three distinct regions: a triadic
region flanking the T-tubules (triadic SR), a region across the Z-line (ZSR), and a region across the M-line (LSR). Note that the ZSR and LSR are represented
in light SR fractions, while the triadic SR is represented in the heavy SR fractions. The upper left enlargement represents a schematic diagram showing
localization of SSPN at the sarcolemma, where it is a core component of the DGC. SSPN is represented as a four-transmembrane-spanning protein with
the color scheme as described in Fig. 1. The sarcoglycans (α-, β-, γ-, δ-SGs; orange) are depicted as transmembrane oval shapes. The SGs and SSPN form a
tight subcomplex within the DGC. Dystrophin (not shown) interacts with β-DG on the cytoplasmic face of the sarcolemma membrane and provides
linkage to the actin cytoskeleton. Dystroglycan (not shown) serves as a receptor for extracellular matrix ligands. The enlargement on the
upper right represents a schematic illustration of the SR membranes where nSPN and μSPN (color scheme as described in Fig. 1) are enriched and
associate with a subset of the SGs (δ-SG, δ-SG3, and γ-SG; orange) [26, 50]. Triadic SR regions contain δ-SG3, nSPN, and μSPN (lower enlargement), but
lack δ-SG and γ-SG as previously described [26, 50]. Data from two-photon laser scanning microscopy reveals that nSPN is mostly associated with the
ZSR and the triadic SR, and only minimally with the LSR. While protein expression of nSPN, μSPN, and SG isoforms in the SR is demonstrated, it is
unclear whether these proteins form a subcomplex within these intracellular membrane structures, which will be the focus of future studies
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Additional files
Additional file 1: Figure S1. nSPN mRNA transcripts are predominant
in skeletal and heart muscles. RT-PCR was performed on cDNA isolated
from various human tissues (skeletal muscle, testis, colon, heart, brain,
breast, and bone marrow) using a forward primer in exon 1 and a reverse
primer in exon 4, as illustrated in Fig. 1c. PCR products were obtained for
μSPN (179 bp) and nSPN (90 bp). RT-PCR performed without template
DNA is shown as a negative control (neg. ctrl). Molecular size markers are
indicated on the left. (PDF 348 kb)
Additional file 2: Figure S2. Nanospan localization is consistent with
triad localization in stretched skeletal muscle fibers. TPLSM study of nSPN
localization in stretched FDB skeletal muscle fibers from wild-type (C57-BL/6J)
mice. Panels A and B are TPLSM images of an FDB muscle simultaneously
labeled with nSPN (Alexa 488) and α-actinin (Texas Red) antibodies. Panel C
shows the superposition of the images on panels A and B. Panels D and E
show simultaneous TPLSM images of immunolocalization of nSPN and the
SHG obtained from an FDB muscle labeled with an antibody against nSPN
(Alexa 488). Panel F shows the superposition of the images on panels D and E.
Panel G corresponds to the superposition of the Alexa 488 (nSPN, green trace)
and Texas Red (α-actinin, red trace) fluorescence plot profiles of the fibers
showed in panels A–C. Panel H corresponds to the superposition of the Alexa
488 emission (nSPN, green trace) and SHG (blue trace) profiles of the fibers
shown in panels D–F (profiles taken from areas indicated with boxes). The
schematic diagrams at the bottom of panels G and H show the
correspondence of the intensity profiles with main sarcomeric hallmarks.
Sarcomeric length of the fibers presented in this figure is ~3.7 μm. Scale bar,
10 μm. (PDF 2028 kb)
Additional file 3: Figure S3. nSPN does not associate with the DGC.
Skeletal microsomes from wild-type (WT) and SSPN-deficient muscle was
solubilized with digitonin and subjected to sWGA enrichment, which
represents the first step in DGC purification. Immunoblot analysis of the
starting material (start), sWGA void, and sWGA eluate probed with antibodies
to α-DG (as a marker for DGC purification) and nSPN (R20). (PDF 118 kb)
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